Navigation Links
Keryx Biopharmaceuticals to Present at the Citigroup 2013 Global Healthcare Conference
Date:2/22/2013

NEW YORK, Feb. 22, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur , the Company's Chief Executive Officer, will be presenting at the Citigroup 2013 Global Healthcare Conference, being held February 25-27, 2013, in New York City.  Mr. Bentsur's presentation is scheduled to take place on Wednesday, February 27th, at 2:15 PM ET. 

A live audio webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has completed a U.S.-based Phase 3 clinical program for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA, and Keryx expects to submit an NDA with the FDA and a MAA with the EMA in the second quarter of 2013.  Zerenex is also in Phase 2 development in the U.S. for the management of phosphorus and iron deficiency in anemic patients with Stage 3 to 5 non-dialysis dependent chronic kidney disease.  In addition, Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. has filed its New Drug Application for marketing approval of ferric citrate in <
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common Stock
2. Keryx Biopharmaceuticals Announces $55 Million Proposed Public Offering of Common Stock
3. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Third Quarter 2012 Financial Results
4. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Second Quarter 2012 Financial Results
5. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
6. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
7. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
8. Biopharmaceutical Industry Veterans Join Inspiration Biopharmaceuticals Board of Directors
9. Alder Biopharmaceuticals Receives $3.5 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2 Clinical Trial of ALD518/BMS-945429 in Crohns Disease
10. Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B
11. Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 23, 2014 UBM Medica US today announced ... online community and information resource for neurologists and other ... their patients with neurological disorders . ... population, necessitates greater access to dedicated information for healthcare ... neurological conditions include: , 1 in 6 ...
(Date:7/23/2014)... OSCEOLA, Wis. and MOUNTAIN VIEW, ... Inc. ("Surpass"), a recognized leader in translational preclinical research, ... at www.surpassinc.com ), signaling the transformation of Surpass, ... integrated innovation partner for our customers. This press release ... that two integral hires were added to the Silicon ...
(Date:7/23/2014)... , July 23, 2014 NOT ... DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE ... LAWS OR REGULATIONS OF SUCH JURISDICTION. AbbVie (NYSE: ... results on Friday, July 25, 2014, before the market opens. ... earnings conference call at 8 a.m. Central time (9 a.m. ...
Breaking Medicine Technology:UBM Medica US Launches NeurologyTimes.com 2UBM Medica US Launches NeurologyTimes.com 3SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 2SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 3AbbVie to Host Second-Quarter Earnings Conference Call 2AbbVie to Host Second-Quarter Earnings Conference Call 3AbbVie to Host Second-Quarter Earnings Conference Call 4AbbVie to Host Second-Quarter Earnings Conference Call 5AbbVie to Host Second-Quarter Earnings Conference Call 6
... , , New collaborative research program to study effects ... Dec. 30 A new research program called the Medication ... to study the effects of prescription medications used during pregnancy. ... Drug Administration and researchers at the HMO Research Network Center ...
... , BOSTON, Dec. 30 Solos Endoscopy, Inc. (Pink ... to a prosperous 2010, following a solid year in 2009, due ... the closing months of 2009, Solos Endoscopy, Inc. has taken the ... of surgical endoscopy instruments. This will allow the MammoView(TM) line to ...
Cached Medicine Technology:FDA, Health Organizations to Study Safety of Medications Taken During Pregnancy 2FDA, Health Organizations to Study Safety of Medications Taken During Pregnancy 3Solos Endoscopy, Inc. Set to Increase Business Through Sales and Product Development in 2010 2
(Date:7/23/2014)... if a suspicious skin lesion is painful or itchy ... to be cancerous, according to a new study headed ... Dermatology at Temple University School of Medicine. , The ... July 23, 2014, found that nearly 36. 9 percent ... 28.2 percent involve pain. Non-melanoma skin cancers specifically, ...
(Date:7/23/2014)... Celebrating a decade of philanthropy in 2014, The ... of $1,070,000 in grants to 20 New Jersey non-profit ... Foundation’s 1,000th grant. , “The Horizon Foundation for New ... community-based organizations that are working to improve public health ... State,” said Robert A. Marino, Horizon Blue Cross Blue ...
(Date:7/23/2014)... Inventor and entrepreneur Delegate Joe T. May will ... pump – sharing his passion for technology and innovation ... , With 24 patents granted and three pending, this ... the General Assembly since Thomas Jefferson. Inventions credited to ... seen on television, an instrument for measuring octane on ...
(Date:7/23/2014)... News) -- Regularly checking the pulse of a stroke ... "Screening pulse is the method of choice for checking ... have never had a stroke. Our study shows it ... to identify people who might need more thorough monitoring ... Bernd Kallmunzer, of Erlangen University in Germany. ...
(Date:7/23/2014)... in Shaanxi province, and the University of California, Davis, ... groundwork for establishing the Sino-U.S. Joint Research Center for ... held in the city of Yingchuan, China, during a ... Agriculture and China,s Ministry of Science and Technology. , ... and for our World Food Center and serves as ...
Breaking Medicine News(10 mins):Health News:Research led by Temple's chair of dermatology: Pain and itch may be signs of skin cancer 2Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 2Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 3Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 4Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 5Health News:Celebrating Innovation and Invention 2Health News:Routine Pulse Check May Prevent Second Stroke, Study Says 2Health News:Global food safety research agreement signed by China and UC Davis 2Health News:Global food safety research agreement signed by China and UC Davis 3
... older women need screening as much as younger ones, ... screening should continue for women older than 50 -- ... because they have a similar level of risk as ... suggested there,s little benefit in repeating smear tests in ...
... recovered from unique virus , , THURSDAY, April 23 (HealthDay ... now been diagnosed with a unique form of swine ... people have recovered, Dr. Anne Schuchat, director of the ... for Immunization and Respiratory Diseases, said during an afternoon ...
... EFFINGHAM, Ill., April 23 Heartland Dental Care, Inc. ... care facilities during first quarter 2009.The six acquisitions include ... Phoenix, Ariz., Glendale, Ariz., and New Port Richie, Fla. ... locations in Lee,s Summit, Mo. and Dulles, Va. This ...
... WASHINGTON, April 23 The Food and Drug Administration ... expanded over-the-counter access to the morning-after pill, Levonorgestrel or ... adults. Deirdre McQuade, Assistant Director for Policy and Communications ... Pro-Life Activities, objected to the move in the following ...
... can be significantly reduced by providing a simple intervention ... and alternatives of various imaging modalities, according to a ... Island, NY. , "Given the increased awareness ... medical imaging we hypothesized that a simple intervention of ...
... Minn. -- An important genetic study conducted through ... alcoholism in subjects with European ancestry, according to ... Experimental Research . , Research findings ... specific genes and their variations associated with this ...
Cached Medicine News:Health News:Don't Lower Age for Cervical Cancer Test, Study Urges 2Health News:Swine Flu Cases Now Total 7: CDC 2Health News:Heartland Dental Care, Inc. Adds Eight Dental Practices In First Quarter 2009 2Health News:Pro-Life Spokeswoman Objects to FDA Approval of 'Morning-After Pill' for Minors Without Prescription 2Health News:Mayo clinic study finds gene bringing together animal and human research in alcoholism 2
... is pouncing on the T.L.I.F. market as the ... of CFRP clinical history and the amazing success ... Leopard is sure to be king of the ... from 7-18 mm in height. The footprint is ...
... provides anterior column support for single or ... to L5. The system consists of one ... that are stacked to a desired height, ... Fiber Reinforced Polymer material emulates the biomechanical ...
Anterior Interbody fusion with proven clinical performance. Large hole design. Request info fda status for sale....
... transmitted through sorted fiberglass bundles ... transmit it to a user's ... designed for rough, industrial handling ... low cost if they should ...
Medicine Products: